State Street Corp Raises Position in Hims & Hers Health, Inc. (NYSE:HIMS)

State Street Corp increased its stake in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 4.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,626,543 shares of the company's stock after buying an additional 206,078 shares during the quarter. State Street Corp owned about 2.15% of Hims & Hers Health worth $85,221,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Nisa Investment Advisors LLC boosted its stake in shares of Hims & Hers Health by 679.2% during the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company's stock valued at $37,000 after purchasing an additional 1,603 shares during the period. Quest Partners LLC increased its holdings in Hims & Hers Health by 5,944.1% during the 2nd quarter. Quest Partners LLC now owns 3,566 shares of the company's stock worth $72,000 after purchasing an additional 3,507 shares during the period. Van ECK Associates Corp bought a new stake in Hims & Hers Health during the 2nd quarter valued at $111,000. CWM LLC grew its position in shares of Hims & Hers Health by 21.4% during the 3rd quarter. CWM LLC now owns 5,982 shares of the company's stock worth $110,000 after buying an additional 1,054 shares in the last quarter. Finally, Quarry LP raised its holdings in shares of Hims & Hers Health by 91.0% in the third quarter. Quarry LP now owns 6,113 shares of the company's stock valued at $113,000 after acquiring an additional 2,913 shares in the last quarter. Institutional investors own 63.52% of the company's stock.

Hims & Hers Health Trading Down 0.4 %

Hims & Hers Health stock traded down $0.13 during midday trading on Tuesday, hitting $31.12. 14,635,490 shares of the stock were exchanged, compared to its average volume of 9,946,161. The stock has a market capitalization of $6.80 billion, a price-to-earnings ratio of 70.09 and a beta of 1.25. The stock's 50-day simple moving average is $25.02 and its 200 day simple moving average is $21.06. Hims & Hers Health, Inc. has a fifty-two week low of $8.09 and a fifty-two week high of $35.02.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings results on Monday, November 4th. The company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business had revenue of $401.56 million for the quarter, compared to analyst estimates of $382.20 million. During the same quarter in the prior year, the company posted ($0.04) EPS. The company's quarterly revenue was up 77.1% on a year-over-year basis. Equities analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Insider Transactions at Hims & Hers Health

In other news, CEO Andrew Dudum sold 188,888 shares of Hims & Hers Health stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $20.88, for a total transaction of $3,943,981.44. Following the sale, the chief executive officer now owns 67,015 shares in the company, valued at approximately $1,399,273.20. The trade was a 73.81 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Oluyemi Okupe sold 269,739 shares of the business's stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $20.31, for a total value of $5,478,399.09. Following the completion of the sale, the chief financial officer now owns 145,763 shares of the company's stock, valued at approximately $2,960,446.53. This represents a 64.92 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,143,575 shares of company stock valued at $27,724,979. 17.71% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on HIMS. TD Cowen reaffirmed a "buy" rating and issued a $28.00 price target on shares of Hims & Hers Health in a research report on Wednesday, November 20th. Bank of America lowered shares of Hims & Hers Health from a "buy" rating to an "underperform" rating and decreased their price target for the company from $32.00 to $18.00 in a research report on Thursday, November 14th. Canaccord Genuity Group raised their target price on shares of Hims & Hers Health from $28.00 to $38.00 and gave the company a "buy" rating in a research note on Monday, December 2nd. Morgan Stanley started coverage on Hims & Hers Health in a research report on Tuesday. They set an "overweight" rating and a $42.00 target price on the stock. Finally, Deutsche Bank Aktiengesellschaft increased their price objective on shares of Hims & Hers Health from $23.00 to $27.00 and gave the company a "hold" rating in a research report on Wednesday, November 6th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average price target of $22.80.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.